A novel fluorophosphonate inhibitor of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol with potential anti-obesity effects

被引:52
|
作者
Bisogno, Tiziana [1 ,8 ]
Mahadevan, Anu [2 ]
Coccurello, Roberto [3 ]
Chang, Jae Won [4 ,5 ]
Allara, Marco [1 ]
Chen, Yugang [2 ]
Giacovazzo, Giacomo [3 ]
Lichtman, Aron [6 ]
Cravatt, Benjamin [4 ,5 ]
Moles, Anna [3 ,7 ]
Di Marzo, Vincenzo [1 ]
机构
[1] CNR, Inst Biomol Chem, Endocannabinoid Res Grp, I-80078 Pozzuoli, NA, Italy
[2] Organix Inc, Woburn, MA USA
[3] IRCCS Fdn Santa Lucia, Cell Biol & Neurobiol Inst IBCN, Rome, Italy
[4] Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA
[5] Scripps Res Inst, Dept Chem Physiol, La Jolla, CA 92037 USA
[6] Virginia Commonwealth Univ, Dept Pharmacol & Toxicol, Richmond, VA USA
[7] Genomnia Srl, Milan, Italy
[8] Univ TorVergat, Dept Expt Med & Biochem Sci, Rome, Italy
关键词
inhibitor; diacylglycerol; cannabinoid; 2-arachidonoylglycerol; serine lipase; anti-obesity effects; HIGH-FAT DIET; ANTAGONISTS; HYDROLYSIS; PREFERENCE; RECEPTORS; OBESITY; SYSTEM;
D O I
10.1111/bph.12013
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background and Purpose The development of potent and selective inhibitors of the biosynthesis of the endocannabinoid 2-arachidonoylglycerol (2-AG) via DAG lipases (DAGL) and is just starting to be considered as a novel and promising source of pharmaceuticals for the treatment of disorders that might benefit from a reduction in endocannabinoid tone, such as hyperphagia in obese subjects. Experimental Approach Three new fluorophosphonate compounds O-7458, O-7459 and O-7460 were synthesized and characterized in various enzymatic assays. The effects of O-7460 on high-fat diet intake were tested in mice. Key Results Of the new compounds, O-7460 exhibited the highest potency (IC50 = 690nM) against the human recombinant DAGL, and selectivity (IC50 > 10M) towards COS-7 cell and human monoacylglycerol lipase (MAGL), and rat brain fatty acid amide hydrolase. Competitive activity-based protein profiling confirmed that O-7460 inhibits mouse brain MAGL only at concentrations 10M, and showed that this compound has only one major off-target', that is, the serine hydrolase KIAA1363. O-7460 did not exhibit measurable affinity for human recombinant CB1 or CB2 cannabinoid receptors (Ki > 10M). In mouse neuroblastoma N18TG2 cells stimulated with ionomycin, O-7460 (10M) reduced 2-AG levels. When administered to mice, O-7460 dose-dependently (012mg center dot kg1, i.p.) inhibited the intake of a high-fat diet over a 14h observation period, and, subsequently, slightly but significantly reduced body weight. Conclusions and Implications O-7460 might be considered a useful pharmacological tool to investigate further the role played by 2-AG both in vitro and in vivo under physiological as well as pathological conditions. Linked Articles This article is part of a themed section on Cannabinoids. To view the other articles in this section visit http://dx.doi.org/10.1111/bph.2013.169.issue-4 & http://dx.doi.org/10.1111/bph.2012.167.issue-8
引用
收藏
页码:784 / 793
页数:10
相关论文
共 50 条
  • [41] Anti-obesity effects of angiotensin converting enzyme inhibitor are mediated by brown adipose tissue activation
    Baiqiang Zhai
    Huiqiao Zhou
    Li Chen
    Wanru Qiu
    Mingsheng Yang
    Yunbo Luo
    Xiaomeng Liu
    Science Bulletin, 2018, 63 (05) : 275 - 277
  • [42] NO-13065: A Novel LPL Activator with Anti-Dyslipidemia and Anti-Obesity Effects in Obese Mice
    Kido, Satoshi
    Yoshioka, Hidenori
    Nakata, Hikaru
    Nishida, Takuto
    Inoue, Yasuhide
    Iwata, Koushi
    OBESITY, 2023, 31 : 134 - 135
  • [43] Effects of meal type on the bioavailability of vutiglabridin, a novel anti-obesity agent, in healthy subjects
    Won, Heejae
    Yoon, Deok Yong
    Lee, Sangmi
    Cho, Joo-Youn
    Oh, Jaeseong
    Jang, In-Jin
    Yoo, Sang-Ku
    Yu, Kyung-Sang
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (03):
  • [44] The endocannabinoid 2-arachidonoylglycerol and dual ABHD6/MAGL enzyme inhibitors display neuroprotective and anti-inflammatory actions in the in vivo retinal model of AMPA excitotoxicity
    Kokona, Despina
    Spyridakos, Dimitris
    Tzatzarakis, Manolis
    Papadogkonaki, Sofia
    Filidou, Eirini
    Arvanitidis, Konstantinos, I
    Kolios, George
    Lamani, Manjunath
    Makriyannis, Alexandros
    Malamas, Michael S.
    Thermos, Kyriaki
    NEUROPHARMACOLOGY, 2021, 185
  • [45] Natural products as novel anti-obesity agents: insights into mechanisms of action and potential for therapeutic management
    Sayed, Ummul Fathima Shaik Mohamed
    Moshawih, Said
    Goh, Hui Poh
    Kifli, Nurolaini
    Gupta, Gaurav
    Singh, Sachin Kumar
    Chellappan, Dinesh Kumar
    Dua, Kamal
    Hermansyah, Andi
    Ser, Hooi Leng
    Ming, Long Chiau
    Goh, Bey Hing
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [46] Novel avocado oil-functionalized yogurt with anti-obesity potential: Technological and nutraceutical perspectives
    Machado, Manuela
    Sousa, Sergio
    Morais, Pilar
    Miranda, Armenio
    Rodriguez-Alcala, Luis M.
    Gomes, Ana Maria
    Pintado, Manuela
    FOOD BIOSCIENCE, 2022, 50
  • [47] Novel methods for extraction of monomeric phenols from plants and fruits with potential anti-obesity activity
    Ganjeh, Alireza Mousakhani
    Pinto, Carlos A.
    Casal, Susana
    Habanova, Marta
    Holovicova, Maria
    Saraiva, Jorge A.
    JOURNAL OF FOOD COMPOSITION AND ANALYSIS, 2025, 141
  • [48] Anti-obesity effects of garlic in uncoupling protein-2 transgenic mice
    Lee, Mak-Soon
    Kim, Yangha
    FASEB JOURNAL, 2009, 23
  • [49] Anti-obesity effects of 3-hydroxychromone derivative, a novel small-molecule inhibitor of glycogen synthase kinase-3
    Lee, Sooho
    Yang, Woo Kyeom
    Song, Ji Ho
    Ra, Young Min
    Jeong, Jin-Hyun
    Choe, Wonchae
    Kang, Insug
    Kim, Sung-Soo
    Ha, Joohun
    BIOCHEMICAL PHARMACOLOGY, 2013, 85 (07) : 965 - 976
  • [50] ANTI-OBESITY PHARMACOTHERAPY AND THE POTENTIAL FOR PREVENTING PROGRESSION FROM PREDIABETES TO TYPE 2 DIABETES
    Garber, Alan J.
    ENDOCRINE PRACTICE, 2015, 21 (06) : 634 - 644